Leveraging gene-environment interactions and endotypes for asthma gene discovery - 04/03/16
, Carole Ober, PhD b, ⁎∗ 
Abstract |
Asthma is a heterogeneous clinical syndrome that includes subtypes of disease with different underlying causes and disease mechanisms. Asthma is caused by a complex interaction between genes and environmental exposures; early-life exposures in particular play an important role. Asthma is also heritable, and a number of susceptibility variants have been discovered in genome-wide association studies, although the known risk alleles explain only a small proportion of the heritability. In this review, we present evidence supporting the hypothesis that focusing on more specific asthma phenotypes, such as childhood asthma with severe exacerbations, and on relevant exposures that are involved in gene-environment interactions (GEIs), such as rhinovirus infections, will improve detection of asthma genes and our understanding of the underlying mechanisms. We will discuss the challenges of considering GEIs and the advantages of studying responses to asthma-associated exposures in clinical birth cohorts, as well as in cell models of GEIs, to dissect the context-specific nature of genotypic risks, to prioritize variants in genome-wide association studies, and to identify pathways involved in pathogenesis in subgroups of patients. We propose that such approaches, in spite of their many challenges, present great opportunities for better understanding of asthma pathogenesis and heterogeneity and, ultimately, for improving prevention and treatment of disease.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, rhinovirus, genome-wide association study, gene-environment interactions, 17q asthma locus, CDHR3
Abbreviations used : CDHR3, COAST, COPSAC2000, eQTL, GEI, GWAS, GWIS, IRF1, IRF5, OR, PASTURE, reQTL, RSV, RV-C, SNP, STAT2, WGCNA
Plan
| Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, and William T. Shearer, MD, PhD |
|
| C.O. is supported by R01 HL058197, U19 AI095230, U01 AI106683, P01 HL070831, and R01 HL129735. K.B. is supported by The Lundbeck Foundation grant no. R163-2013-16235 & R16-A1694; The Danish Ministry of Health grant no. 903516; Danish Council for Strategic Research grant no. 0603-00280B; The Danish Council for Independent Research grant no. 10-082884 & 271-08-0815; and The Capital Region Research Foundation (no grant no.). |
|
| Disclosure of potential conflict of interest: C. Ober has received grants from the National Institutes of Health. K. Bønnelykke declares that he has no relevant conflicts of interest. |
|
| Terms in boldface and italics are defined in the glossary on page 668. |
Vol 137 - N° 3
P. 667-679 - mars 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
